About AMP®
The goal of the Accelerating Medicines Partnership® (AMP®) Program is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment.
Overview
The goal of the Accelerating Medicines Partnership® (AMP®) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment. (Read the program description by NIH here.) Collaborations with 10 companies and three NIH Institutes have been established across five major disease areas: Alzheimer's disease, Type 2 diabetes, Rheumatoid Arthritis (RA)/Lupus, Parkinson's disease and Schizophrenia.
Partners
Private-Sector Partners:
- AbbVie*
- Biogen*
- Bristol-Myers Squibb Company*
- Eli Lilly and Company*
- GlaxoSmithKline*
- Johnson & Johnson*
- Merck & Co., Inc.*
- Novartis Institutes for BioMedical Research*
- Pfizer Inc*
- Pharmaceutical Research and Manufacturers of America*
- Sanofi*
- Takeda Pharmaceuticals International, Inc.*
- UCB*
*Provided financial or in-kind support for this program.
FNIH Contact
- Steve Hoffmann, Associate Vice President, Research Partnerships, shoffmann@fnih.org
Related Resources
- Accelerating Medicines Partnership® Program
- Accelerating Medicines Partnership® Program - Alzheimer's Disease
- Accelerating Medicines Partnership® Program Bespoke Gene Therapy Consortium (AMP® BGTC)
- Accelerating Medicines Partnership® Program—Common Metabolic Diseases
- Accelerating Medicines Partnership® Program - Parkinson's Disease
- Accelerating Medicines Partnership® Program: Rheumatoid Arthritis, Systematic Lupus Erythematosus & Related Autoimmune Disorders
- Accelerating Medicines Partnership® Program – Schizophrenia (AMP® SCZ)
- Accelerating Medicines Partnership® Program – Type 2 Diabetes Project
Related Videos
Accelerating Medicines Partnership® Program - Alzheimer's Disease
Accelerating Medicines Partnership® Program - Common Metabolic Diseases
Accelerating Medicines Partnership® Program Bespoke Gene Therapy
Accelerating Medicines Partnership® Program - RA/Lupus Project
Accelerating Medicines Partnership® Program – Type 2 Diabetes Project
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.